Digestive Remedies in Lithuania

October 2023 | 22 pages | ID: D8CA786189DEN
Euromonitor International Ltd

Abstracts

The digestive category is not very active within Lithuania. Despite this, in 2023, sales are returning to a pre-pandemic state. Proton pump inhibitors are gaining a share, which was lost by H2 blockers, with brands such as Nolpaza doing well in this situation. The latter product is praised for blocking the final step in the pathway of acid secretion in the stomach, while the former blocks only one of the first stimuli for acid production.

Euromonitor International's Digestive Remedies in Lithuania report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2018-2022, allowing you to identify the sectors driving growth. Forecasts to 2027 illustrate how the market is set to change.

Product coverage: Diarrhoeal Remedies, IBS Treatments, Indigestion and Heartburn Remedies, Laxatives, Motion Sickness Remedies, Paediatric Digestive Remedies.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Digestive Remedies market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

DIGESTIVE REMEDIES IN LITHUANIA
KEY DATA FINDINGS
2023 DEVELOPMENTS
Proton pump inhibitors gain share as Escadra rises in popularity 
International players continue to dominate, with limited local players available 
No significant innovation leads to limited results in 2023 
PROSPECTS AND OPPORTUNITIES
Healthier living and less fatty foods challenge sales of digestive products 
Digestive enzymes remain popular, with Mezym benefiting from being natural 
The ageing population drives growth for digestive remedies 
CATEGORY DATA
Table 1 Sales of Digestive Remedies by Category: Value 2018-2023
Table 2 Sales of Digestive Remedies by Category: % Value Growth 2018-2023
Table 3 NBO Company Shares of Digestive Remedies: % Value 2019-2023
Table 4 LBN Brand Shares of Digestive Remedies: % Value 2020-2023
Table 5 Forecast Sales of Digestive Remedies by Category: Value 2023-2028
Table 6 Forecast Sales of Digestive Remedies by Category: % Value Growth 2023-2028
CONSUMER HEALTH IN LITHUANIA
EXECUTIVE SUMMARY
Consumer health in 2023: The big picture
2023 key trends
Competitive landscape
Retailing developments 
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2018-2023
Table 8 Life Expectancy at Birth 2018-2023
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2018-2023
Table 10 Sales of Consumer Health by Category: % Value Growth 2018-2023
Table 11 NBO Company Shares of Consumer Health: % Value 2019-2023
Table 12 LBN Brand Shares of Consumer Health: % Value 2020-2023
Table 13 Penetration of Private Label by Category: % Value 2018-2023
Table 14 Distribution of Consumer Health by Format: % Value 2018-2023
Table 15 Distribution of Consumer Health by Format and Category: % Value 2023
Table 16 Forecast Sales of Consumer Health by Category: Value 2023-2028
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2023-2028
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
SOURCES
Summary 1 Research Sources